{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:31:41Z","timestamp":1792096301179,"version":"4.4.0"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The\nin vitro activity of DX-619, a new des-F(6) quinolone, against\nanaerobic bacteria was evaluated. DX-619 showed potent activity against\n            <jats:italic>Bacteroides<\/jats:italic>\n            ,\n            <jats:italic>Prevotella<\/jats:italic>\n            ,\n            <jats:italic>Fusobacterium<\/jats:italic>\n            ,\n            <jats:italic>Micromonas<\/jats:italic>\n            ,\n            <jats:italic>Actinomyces<\/jats:italic>\n            , and\n            <jats:italic>Clostridium<\/jats:italic>\n            spp., with MIC\n            <jats:sub>50<\/jats:sub>\n            s\/MIC\n            <jats:sub>90<\/jats:sub>\n            s of \u22640.03 to\n0.25\/\u22640.03 to 1 \u03bcg\/ml, respectively. DX-619 was also\nactive against imipenem-resistant\n            <jats:italic>Bacteroides<\/jats:italic>\n            spp., with\nMIC\n            <jats:sub>50<\/jats:sub>\n            s\/MIC\n            <jats:sub>90<\/jats:sub>\n            s of 0.25\/1 \u03bcg\/ml,\nrespectively.\n          <\/jats:p>","DOI":"10.1128\/aac.00639-06","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T20:58:50Z","timestamp":1161809930000},"page":"3908-3913","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["In Vitro Antianaerobic Activity of DX-619, a New Des-Fluoro(6)Quinolone"],"prefix":"10.1128","volume":"50","author":[{"given":"Kaori","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[{"name":"Division of Anaerobe Research, Life Science Research Center, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken'ichi","family":"Nakao","sequence":"additional","affiliation":[{"name":"Division of Anaerobe Research, Life Science Research Center, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunitomo","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Anaerobe Research, Life Science Research Center, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1128\/AAC.43.9.2320","volume":"43","year":"1999","unstructured":"Betriu, C., M. Gomez, M. L. Palau, A. Sanchez, and J. J. Picazo. 1999. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Amtimicrob. Agents Chemother.43:2320-2322.","journal-title":"Amtimicrob. Agents Chemother."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3325-3333.2005"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2459"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1075-9964(95)80340-8","volume":"1","year":"1995","unstructured":"Finegold, M. S. 1995. Anaerobic infections in humans: an overview. Anaerobe1:3-9.","journal-title":"Anaerobe"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.3040-3045.2005"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/381551"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.5.1158"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2231"},{"key":"e_1_3_1_10_2","unstructured":"Holdman L. V. and W. E. C. Moor. 1997\n. Anaerobic laboratory manual 4th ed. Virginia\nPolytechnic Institute and State University Blacksburg Va."},{"key":"e_1_3_1_11_2","unstructured":"Jousimies-Somer H. R. P. Summanen D. M. Citron E. J.\nBaron H. M. Wexler and S. M. Finegold. 2002\n. Wadsworth-KTL anaerobic bacteriology manual 6th ed.\nStar Publishing Co. Belmont Calif."},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/clinids\/23.Supplement_1.S31","volume":"23","year":"1996","unstructured":"Kato, N., H. Kato, K. Tanaka-Bandoh, K. Watanabe, and K. Ueno. 1996 . Comparison of in vitro activities of Du-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.Clin. Infect. Dis.23(Suppl. 1):S31-S35.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/jac\/40.5.631","volume":"40","year":"1997","unstructured":"Kato, N., H. Kato, K. Tanaka-Bandoh, K. Watanabe, and K. Ueno. 1997 . Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria. J. Antimicrob. Chemother.40:631-637.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051639"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1503\/cmaj.051212","volume":"173","year":"2005","unstructured":"Louie, T. J. 2005. How should we respond to the highly toxogenic NAP1\/ ribotype 027 strain of Clostridium difficile?Can. Med. Assoc. J.173:1049-1050.","journal-title":"Can. Med. Assoc. J."},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1102-1107.2000"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1887-1889.2006"},{"key":"e_1_3_1_18_2","unstructured":"National\nCommittee for Clinical Laboratory Standards. 2001.\nMethods for antimicrobial testing of anaerobic bacteria. Approved\nstandard\u20145th ed. NCCLS document M11-A5. National Committee for\nClinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_1_19_2","first-page":"1254","volume":"40","year":"2005","unstructured":"Pepin, J., N. Saheb, M.-A. Coulombe, M.-E. Alary, M.-P. Corriveau, S. Authier, M. Leblanc, G. Eivard, M. Bettez, V. Primeau, M. Nguyen, C.-E. Jacob, and L. Lanthier. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis.40:1254-1260.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1041104"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2783"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3276-3279.2002"},{"key":"e_1_3_1_23_2","unstructured":"Summanen P. E. J. Baron D. M. Citron C. A.\nStrong H. M. Wexler and S. M. Finegold. 1993\n. Wadsworth anaerobic bacteriology manual 5th ed.\nStar Publishing Co. Belmont Calif."},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1077"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1093\/clinids\/20.Supplement_2.S352","volume":"20","year":"1995","unstructured":"Tanaka-Bandoh, K., N. Kato, K. Watanabe, and K. Ueno. 1995. Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992.Clin. Infect. Dis.20(Suppl. 2):S352-S355.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.1.177"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.9.2232"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00639-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00639-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:59:25Z","timestamp":1645469965000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00639-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1128\/AAC.00639-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.00639-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"2006-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}